Revitope Oncology, Inc. is a privately owned company in Cambridge, MA, that focuses on the development of next-generation T cell engager immunotherapies for a variety of solid cancer indications. Revitope’s platform is a suite of proprietary and modular bispecific antibodies designed to deliver improved therapeutic efficacy and safety through built-in control mechanisms that enable exquisite tumor-specificity. The company has several cancer programs in preclinical development and expects to have its lead program in the clinic by early 2023.

Related Links

https://www.nature.com/articles/d43747-021-00131-w

Reader Interactions

Leave A Reply